Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.42 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118120 | 0.88 | MGLL (0.45) | MGLLPOLBKMT2AALDH1A1MAPT | |
| SCHEMBL21151261 | 0.88 | ADRB1 (0.47) | MGLLPOLBKMT2AALDH1A1MAPT | |
| SCHEMBL20118053 | 0.84 | MGLL (0.41) | MGLLPOLBKMT2AALDH1A1MAPT | |
| SCHEMBL20118127 | 0.84 | MGLL (0.41) | MGLLPOLBKMT2AALDH1A1MAPT | |
| SCHEMBL20118393 | 0.84 | GAA (0.43) | MGLLPOLBALDH1A1MAPTTSHR | |
| SCHEMBL20118229 | 0.84 | MGLL (0.41) | MGLLPOLBKMT2AALDH1A1MAPT | |
| SCHEMBL12542699 | 0.79 | CYP3A4 (0.49) | POLBKMT2AALDH1A1MAPTTSHR | |
| SCHEMBL20118126 | 0.79 | MKNK1 (0.43) | MGLLKMT2AALDH1A1TSHRPGR | |
| SCHEMBL20118398 | 0.79 | MKNK1 (0.43) | MGLLKMT2AALDH1A1TSHRPGR | |
| SCHEMBL13879461 | 0.77 | MGLL (0.51) | MGLLPOLBKMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | MGLL 2140/4885POLB 171/4885KMT2A 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.